EP Patent

EP2525788A2 — Novel retigabine composition

Assigned to Glaxo Group Ltd · Expires 2012-11-28 · 13y expired

What this patent protects

The present invention relates to an oral dosage form comprising N -(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine) or a pharmaceutically acceptable salt or solvate thereof, to a process for preparing such a dosage form and to the use of such a dosage…

USPTO Abstract

The present invention relates to an oral dosage form comprising N -(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine) or a pharmaceutically acceptable salt or solvate thereof, to a process for preparing such a dosage form and to the use of such a dosage form in medicine.

Drugs covered by this patent

Patent Metadata

Patent number
EP2525788A2
Jurisdiction
EP
Classification
—
Expires
2012-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.